Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 50 of 114, showing 5 Applications out of 567 total, starting on record 246, ending on 250

# Protocol No Study Title Investigator(s) & Site(s)

246.

ECCT/25/03/06   Sparkle Study-Site 1404
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Godfrey Allan Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
6. Gertrudes Children’s Hospital (Nairobi City county)
 
View

247.

ECCT/25/03/07   Sparkle - Site 1405
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Prof Videlis Nduba
Site(s) in Kenya
1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county)
2. Ahero Clinical trials Unit (Kisumu county)
3. International Cancer institute (Uasin Gishu county)
4. Kondele Childrens Hospital (Kisumu county)
5. Gertrudes Children’s Hospital (Nairobi City county)
6. Victoria Biomedical Research Institute (Kisumu county)
 
View

248.

ECCT/24/08/06   KALUMA Study
    A randomized, open-label, multicenter study to compare efficacy, safety and tolerability of KLU156 with Coartem® in the treatment of uncomplicated Plasmodium falciparum malaria in adults and children ≥ 5 kg body weight followed by an Extension phase with repeated KLU156 treatment    
Principal Investigator(s)
1. Dr Patricia Odera Ojwang
2. Dr. Bernhards Ogutu
3. Dr.Bernhards Ogutu
Site(s) in Kenya
1. Site 1600: Kenya Medical Research Institute/Centre for Global Health Research Siaya (Siaya county)
2. Site 1601:Kombewa Clinical Research Centre (Kisumu county)
3. Ahero Clinical Trial Unit (Kisumu county)
 
View

249.

ECCT/24/11/01   Sparkle
    A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises   
Principal Investigator(s)
1. Lucas Otieno Tina
Site(s) in Kenya
1. Site 1401:Victoria Biomedical Research Institute (Kisumu county)
2. Site 1402:Ahero Clinical trials Unit (Kisumu county)
3. Site 1403:International Cancer institute (Uasin Gishu county)
4. Site 1404:Kondele Childrens Hospital (Kisumu county)
5. Site 1405:KEMRI/CRDR KEMRI Clinical Research Annex (Kisumu county)
6. Site 1406:Gertrudes Children’s Hospital (Nairobi City county)
 
View

250.

ECCT/16/09/03   Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya.
    Effect of Schistosoma mansoni infection on incidence of Plasmodium falciparum malaria among 1-5 year old children in western Kenya.   
Principal Investigator(s)
1. Dr.Pauline NM Mwinzi
Site(s) in Kenya
KEMRI CGHR
 
View